# Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

> **NCT01022853** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 6727
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01022853
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022853, "Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01022853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*